Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
AL

NASDAQ · ALGS

Aligos Therapeutics, Inc.

Healthcare · Biotechnology

$4.80

Down-$0.23 (-4.57%)

Updated Nov 1, 2026, 10:50 AM

SID Score

3.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
43.26M
P/E ratio
-0.84
Dividend yield
0.00%
52-week range
$3.98 – $8.97
Volume
23.85K
Avg. volume
68.51K

Price performance · ALGS

ALGS price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

ALGS closed at $4.80 after 20 trading sessions, down 11.11% for the selected period.

Last close
$4.80
Period change
-11.11%
Period low
$4.65
Period high
$5.53
Daily close
View OHLC price history
ALGS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$4.99$5.05$4.7501$4.8023.85K
Oct 29, 2026$5.02$5.375$5.02$5.0347.2K
Oct 28, 2026$4.66$5.26$4.66$5.1723.45K
Oct 27, 2026$4.67$4.81$4.63$4.749.53K
Oct 26, 2026$4.98$4.98$4.55$4.6533K
Oct 23, 2026$4.76$4.92$4.65$4.784.85K
Oct 22, 2026$5.005$5.005$4.78$4.8215.25K
Oct 21, 2026$4.88$5.2348$4.88$4.9613.13K
Oct 20, 2026$4.74$5.2408$4.74$5.0342.81K
Oct 19, 2026$4.95$5.08$4.61$4.8482.02K
Oct 16, 2026$5.32$5.50$4.86$4.8667.55K
Oct 15, 2026$5.40$5.409$5.186$5.3925.47K
Oct 14, 2026$5.50$5.5999$5.21$5.2360.56K
Oct 13, 2026$5.465$5.60$5.20$5.5133.97K
Oct 12, 2026$5.50$5.64$5.30$5.5357.27K
Oct 9, 2026$5.27$5.4419$5.27$5.349.06K
Oct 8, 2026$5.25$5.53$5.08$5.3137.37K
Oct 7, 2026$5.33$5.525$5.2301$5.3219.41K
Oct 6, 2026$5.46$5.53$5.3103$5.3812.84K
Oct 5, 2026$5.57$5.65$5.35$5.4048.61K

Latest ALGS news

The latest Smart Investors Daily articles mentioning ALGS.

Stock researchCompany · Overview

ALGS research

Overview

Company profile and research snapshot.

Company profile

Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$3.00
Implied upside
—
Analysts
10
ALGS recent ratings
DateFirmRatingTarget
May 28, 2026Lake StreetBuy—
May 21, 2026Cantor FitzgeraldOverweight—
Mar 26, 2026WestPark CapitalBuy—
Mar 11, 2026HC Wainwright & Co.Buy—
Jan 7, 2026UBSBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 5, 2026

Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced five abstracts have been accepted for presentation at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting® 2026, being held November 5 – 9, 2026 in Denver, CO. The abstracts released today can be found on

Yahoo · Sep 2, 2026

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the Cantor Global Healthcare Conference. Cantor Global Healthcare Conference Fireside Chat on Wednesday, September 9, 2026 at 8:00am ET The presentation will premiere at the time listed above

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By